Notice of interruption or termination of supply of a human drug
 DateHolderCodeDrugDate fromSubject ▲
 17.4.2019ratiopharm GmbH (RAT)21205Telmisartan ratiopharm 80 mg (tbl 28x80 mg (blis.Al/Al))1.8.2019Z
 17.4.2019TEVA Pharmaceuticals Slovakia s.r.o. (TEV-SK)93260HERPESIN 250 (plv inf 10x250 mg (liek.skl.))1.8.2019Z
 15.4.2019Glenmark Pharmaceuticals s.r.o. (GLM-CZ)7056ATelmark Plus 80 mg/25 mg (tbl 30x80 mg/25 mg (blis.Al/Al))30.4.2019Z
 15.4.2019Eli Lilly Nederland B.V. (LIL-NL-2)41437ALIMTA 500 mg prášok na infúzny koncentrát (plc ifc 1x500 mg (liek.inj.skl.))31.7.2019Z
 15.5.2019GALDERMA INTERNATIONAL (GAD)5013BMirvaso 3 mg/g gél (gel 1x10 g (tuba PE/EAA kopolymér/Al/EAA kopolymér/PE))20.5.2019Z
 10.5.2019CANDE s.r.o. (CRR-SK)1965BSTALEMED 50 mg/12,5 mg/200 mg (tbl flm 100x50 mg/12,5 mg/200 mg (fľ.HDPE))29.6.2019Z
 18.4.2019Actavis Group PTC ehf. (ACT-5)79737Irbesartan Actavis 150 mg (tbl flm 28x150 mg (blis.PVC/PVDC/Al))25.4.2019Z
 18.4.2019Actavis Group PTC ehf. (ACT-5)80003Irbesartan Actavis 150 mg (tbl flm 84x150 mg (blis.PVC/PVDC/Al))24.1.2019Z
 18.4.2019Actavis Group PTC ehf. (ACT-5)80013Irbesartan Actavis 300 mg (tbl flm 28x300 mg (blis.PVC/PVDC/Al))25.4.2019Z
 18.4.2019Actavis Group PTC ehf. (ACT-5)80019Irbesartan Actavis 300 mg (tbl flm 30x300 mg (fľ.HDPE))25.4.2019Z
 18.4.2019Actavis Group PTC ehf. (ACT-5)80020Irbesartan Actavis 300 mg (tbl flm 60x300 mg (fľ.HDPE))15.12.2019Z
 18.4.2019Actavis Group PTC ehf. (ACT-5)80016Irbesartan Actavis 300 mg (tbl flm 84x300 mg (blis.PVC/PVDC/Al))1.10.2019Z
 26.4.2019Mylan Ireland Limited (MNY)06658Omeprazol Mylan 20 mg (cps end 30x20 mg (blis.Al/PA/PVC))30.4.2019Z
 24.4.2019GlaxoSmithKline Consumer Healthcare Czech Republic s.r.o. (GAG-CZ)37364Voltaren Emulgel (gel 1x50 g (tuba lamin.LDPE/Al/HDPE))24.4.2019Z
 20.5.2019B.Braun Melsungen AG (BME)05635NuTRIflex Omega special (emu inf 5x1250 ml (vak PA/PP -viackomor.))20.5.2019Z

Subject means: R-Break, O-Renew or Z-Cancellation of human drug delivery


Date from
From
To